Compare RKLB & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RKLB | TAK |
|---|---|---|
| Founded | 2006 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.7B | 43.3B |
| IPO Year | N/A | N/A |
| Metric | RKLB | TAK |
|---|---|---|
| Price | $90.71 | $16.31 |
| Analyst Decision | Buy | |
| Analyst Count | 14 | 0 |
| Target Price | ★ $51.42 | N/A |
| AVG Volume (30 Days) | ★ 29.0M | 2.6M |
| Earning Date | 02-26-2026 | 01-29-2026 |
| Dividend Yield | N/A | ★ 3.20% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | $554,535,000.00 | ★ $29,846,840,032.00 |
| Revenue This Year | $40.29 | N/A |
| Revenue Next Year | $46.77 | $0.47 |
| P/E Ratio | ★ N/A | $118.21 |
| Revenue Growth | ★ 52.42 | N/A |
| 52 Week Low | $14.71 | $12.80 |
| 52 Week High | $92.19 | $16.48 |
| Indicator | RKLB | TAK |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 69.60 |
| Support Level | N/A | $15.87 |
| Resistance Level | N/A | $16.48 |
| Average True Range (ATR) | 0.00 | 0.19 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 0.00 | 84.50 |
Rocket Lab Corp is engaged in space, building rockets, and spacecraft. It provides end-to-end mission services that provide frequent and reliable access to space for civil, defense, and commercial markets. It designs and manufactures the Electron and Neutron launch vehicles and Photon satellite platform. Rocket Lab's Electron launch vehicle has delivered multiple satellites to orbit for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. The business operates in two segments Launch Services and Space Systems. Geographically it serves Japan, Germany, and rest of the world and earns key revenue from the United States.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.